Suicide gene therapy and the control of graft-vs-host disease

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 3 SPEC.ISS., 2004, Pages 453-463

  Introna, Martino ^a   Rambaldi, Alessandro ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Bone marrow transplantation; CD20; CD34; dLNGFr; GVHD; Suicide gene; TK

Indexed keywords

ADENOVIRUS VECTOR; AP 1903; CD20 ANTIGEN; CD34 ANTIGEN; COMPLEMENTARY DNA; FK 506 BINDING PROTEIN; GANCICLOVIR; IMMUNOGLOBULIN; INTERLEUKIN 2; LIGAND; NERVE GROWTH FACTOR; NUCLEOSIDE ANALOG; OKT 3; PHOSPHOGLYCERATE KINASE; PRODRUG; RETROVIRUS VECTOR; RITUXIMAB; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE MODEL; DONOR; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; GENE TRANSFER; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SUICIDE GENE; SUICIDE GENE THERAPY; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

EID: 7744242762     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.05.013     Document Type: Article

References (58)

1. Springer C.J. Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy Journal of Clinical Investment 105 2000 1161-1167
2. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy Cancer Research 46 1986 5276-5281
3. Borrelli E. Heyman R. Hsi M. Evans R.M. Targeting of an inducible toxic phenotype in animal cells Proceedings of the National Academy of Sciences, USA 85 1988 7572-7576
4. Heyman R.A. Borrelli E. Lesley J. et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency Proceedings of the National Academy of Sciences USA 86 1989 2698-2702
5. Fyfe J.A. Keller P.M. Furman P.A. Miller R.L. Elion G.B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine Journal of Biological Chemistry 253 1978 8721-8727
6. Tiberghien P. Reynolds C.W. Keller J. et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84 1994 1333-1341
7. Contassot E. Ferrand C. Certoux J.M. et al. Retrovirus-mediated transfer of the herpes simplex type I thymidine kinase gene in alloreactive T lymphocytes Human Gene Therapy 9 1998 73-80
8. Gallot G. Hallet M.M. Gaschet J. et al. Human HLA-specific T-cell clones with stable expression of a suicide gene: A possible tool to drive and control a graft-versus-host-graft-versus-leukemia reaction? Blood 88 1996 1098-1103
9. Munshi N.C. Govindarajan R. Drake R. et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir Blood 89 1997 1334-1340
10. Cohen J.L. Boyer O. Salomon B. et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes Blood 89 1997 4636-4645
11. Helene M. Lake-Bullock V. Bryson J.S. Jennings C.D. Kaplan A.M. Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene Journal of Immunology 158 1997 5079-5082
12. Cohen J.L. Boyer O. Klatzmann D. Would suicide gene therapy solve the T cell dilemma of allogeneic bone marrow transplantation Immunology Today 20 1999 172-176
13. Cohen J.L. Boyer O. Klatzmann D. Suicide gene therapy of graft-versus-host disease: Immune reconstitution with transplanted mature T cells Blood 98 2001 2071-2076
14. Tiberghien P. Cahn J.Y. Brion A. et al. Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: A phase I-II study Human Gene Therapy 8 1997 615-624
15. Bordignon C. Bonini C. Verzeletti S. et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation Human Gene Therapy 6 1995 813-819
16. Bonini C. Ferrari G. Verzeletti S. et al. HSV-TK gene transfer into donor lymphocytes for control of allogenic graft-versus-leukemia Science 276 1997 1719-1724
17. Cohen J.L. Saron M.F. et al. Boyer O. Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease Human Gene Therapy 11 2000 2473-2481
18. Litvinova E. Maury S. Boyer O. et al. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease Blood 100 2002 2020-2025
19. Verzeletti S. Bonini C. Marktel S. et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors Human Gene Therapy 9 1998 2243-2251
20. Bonini C. Ciceri F. Apperley J.F. et al. Hsv-Tk engineered donor lymphocytes provide early immune reconstitution and control of GVHD after haplo-identical hemapoietic stem cell transplantation Blood 102 2003 155a
21. Tiberghien P. Ferrand C. Lioure B. et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft Blood 97 2001 63-72
22. Aubin F. Cahn J.Y. Ferrand C. Angonin R. Humbert P. Tiberghien P. Extensive vitiligo after ganciclovir treatment of GvHD in a patient who had received donor T cells expressing herpes simplex virus thymidine kinase Lancet 355 2000 626-627
23. Burt R.K. Drobyski W.R. Seregina T. et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions Experimental Hematology 31 2003 903-910
24. Sauce D. Rufer N. Mercier P. et al. Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells Blood 102 2003 1241-1248
25. Riddell S.R. Greenberg P.D. Overell R.W. et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant Human Gene Therapy 3 1992 319-338
26. Riddell S.R. Elliott M. Lewinsohn D.A. et al. T-cell mediated rejection of gene modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients Natural Medicine 2 1996 216-223
27. Ferrand C. Robinet E. Contassot E. et al. Retrovirus mediated gene transfer in primary T lymphocytes: Influence of the transduction/selection process and of ex vivo expansion on the T cell receptor b chain hypervariable region repertoire Human Gene Therapy 11 2000 1151-1164
28. Dietrich P.Y. Walker P.R. Schnuriger V. et al. TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture International Immunology 9 1997 1073-1083
29. Movassagh M. Boyer O. Burland M.C. Leclercq V. Klatzmann D. Lemoine F.M. Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection Human Gene Therapy 11 2000 1189-1200
30. Qasim W. King D. Buddle J. et al. The impact of retroviral suicide gene transduction procedures on T cells British Journal of Haematology 123 2003 712-719
31. Marktel S. Magnani Z. Ciceri F. et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T cell-depleted stem cell transplantation Blood 3 2002 3
32. Dardalhon V. Jaleco S. Rebouissou C. et al. Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector Blood 96 2000 885-893
33. Orchard P.J. Blazar B.R. Burger S. et al. Clinical-scale selection of anti-CD3/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor Human Gene Therapy 13 2002 979-988
34. Kolen S. Weijtens M. Hagenbeek A. et al. Monitoring of developing graft-versus-host disease mediated by herpes simplex virus thymidine kinase gene-transduced T cells Human Gene Therapy 14 2003 341-351
35. Weijtens M. van Spronsen A. Hagenbeek A. Braakman E. Martens A. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats Human Gene Therapy 13 2002 187-198
36. Garin M.I. Garrett E. et al. Tiberghien P.Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene Blood 97 2001 122-129
37. Singh S. Cunningham C. Buchanan A. Jolly D.J. Nemunaitis J. Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer Molecular Therapy 4 2001 157-160
38. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme Human Gene Therapy 11 2000 2389-2401
39. Ram Z. Culver K. Oshiro E.M. et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Natural Medicine 3 1997 1354-1361
40. Palu G. Cavaggioni A. Calvi P. et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans Gene Therapy 6 1999 330-337
41. Trask T.W. Trask R.P. Aguilar-Cordova E. et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors Molecular Therapy 1 2000 195-203
42. Black M.E. Kokoris M.S. Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing Cancer Research 61 2001 3022-3026
43. Rettig M.P. Ritchey J.K. Meyerrose T.E. Haug J.S. DiPersio J.F. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease Molecular Therapy 8 2003 29-41
44. Fehse B. Kustikova O.S. Li Z. et al. A novel sort-suicide fusion gene vector for T cell manipulation Gene Therapy 9 2002 1633-1638
45. Qasim W. Thrasher A.J. Buddle J. Kinnon C. Black M.E. Gaspar H.B. T cell transduction and suicide with an enhanced mutant thymidine kinase Gene Therapy 9 2002 824-827
46. Aints A. Belusa R. Andersson R.M. Guven H. Dilber M.S. Enhanced ouabain resistance gene as a eukaryotic selection marker Human Gene Therapy 13 2002 969-977
47. Ashkenazi A. Dixit V.M. Death receptors: Signaling and modulation Science 281 1998 1305-1308
48. Thomis D.C. Marktel S. Bonini C. et al. Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease Blood 97 2001 1249-1257
49. Berger C. Blau C.A. Huang M.L. et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model Blood 103 2004 1261-1269
50. Junker K. Koehl U. et al. Zimmerman S.Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes Gene Therapy 10 2003 1189-1197
51. Introna M. Barbui A.M. Bambacioni F. et al. Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies Human Gene Therapy 11 2000 611-620
52. Golay J. Zaffaroni L. Vaccari T. et al. Biological response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement mediated lysis Blood 95 2000 3900-3908
53. Leget G.A. Czuczman M.S. Use of rituximab, the new FDA-approved antibody Current Opinion in Oncology 10 1999 548-551
54. McLaughlin P. Grillo-Lopez A.J. Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program Journal of Clinical Oncology 16 1998 2825-2833
55. Reff M.E. Carner K. Chambers K.S. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435-445
56. Serafini M. Manganini M. Borleri G.M. Characterization of CD20 transduced T lympgocytes for an alternative gene therapy approach for the treatment of graft versus host disease Human Gene Therapy 2004 15 63-76
57. Serafini M. Bonamino M. Golay J. Introna M. EF1-alpha promoter in a lentiviral backbone improves the CD20 suicide gene expression in human primary T lymphocytes allowing efficient rituximab-mediated lysis Haematologica 2004 89 86-95
58. van Rijn R.S. Simonetti E.R. Hagenbeek A. et al. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice Blood 102 2003 2522-2531